Novo Nordisk A/S (NYSE: NVO) Stock Competitors & Peer Comparison

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while LLY trades at $1,179.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas LLY's P/E ratio is 37.15. In terms of profitability, NVO's ROE is +0.59%, compared to LLY's ROE of +0.93%. Regarding short-term risk, NVO is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for NVO.Check LLY's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, JNJ has a market cap of 618B. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while JNJ trades at $261.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas JNJ's P/E ratio is 23.90. In terms of profitability, NVO's ROE is +0.59%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, NVO is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for NVO.Check JNJ's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, ABBV has a market cap of 481.4B. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while ABBV trades at $276.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas ABBV's P/E ratio is 26.74. In terms of profitability, NVO's ROE is +0.59%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, NVO is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for NVO.Check ABBV's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, MRK has a market cap of 351.7B. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while MRK trades at $145.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas MRK's P/E ratio is 44.36. In terms of profitability, NVO's ROE is +0.59%, compared to MRK's ROE of +0.07%. Regarding short-term risk, NVO is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for NVO.Check MRK's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, NVS has a market cap of 272B. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while NVS trades at $143.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas NVS's P/E ratio is 16.47. In terms of profitability, NVO's ROE is +0.59%, compared to NVS's ROE of +0.30%. Regarding short-term risk, NVO is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for NVO.Check NVS's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, AZN has a market cap of 246.2B. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while AZN trades at $159.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas AZN's P/E ratio is 17.14. In terms of profitability, NVO's ROE is +0.59%, compared to AZN's ROE of +0.22%. Regarding short-term risk, NVO is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for NVO.Check AZN's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, AMGN has a market cap of 219.9B. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while AMGN trades at $414.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas AMGN's P/E ratio is 18.21. In terms of profitability, NVO's ROE is +0.59%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, NVO is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for NVO.Check AMGN's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, GILD has a market cap of 182.4B. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while GILD trades at $151.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas GILD's P/E ratio is -377.18. In terms of profitability, NVO's ROE is +0.59%, compared to GILD's ROE of -0.16%. Regarding short-term risk, NVO is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for NVO.Check GILD's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, PFE has a market cap of 158.7B. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while PFE trades at $28.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas PFE's P/E ratio is 9.13. In terms of profitability, NVO's ROE is +0.59%, compared to PFE's ROE of +0.05%. Regarding short-term risk, NVO is less volatile compared to PFE. This indicates lower risk in terms of short-term price fluctuations for NVO.Check PFE's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, BMY has a market cap of 121.7B. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while BMY trades at $59.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas BMY's P/E ratio is 10.04. In terms of profitability, NVO's ROE is +0.59%, compared to BMY's ROE of +0.47%. Regarding short-term risk, NVO is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for NVO.Check BMY's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, SNY has a market cap of 96.6B. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while SNY trades at $40.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas SNY's P/E ratio is 8.76. In terms of profitability, NVO's ROE is +0.59%, compared to SNY's ROE of +0.06%. Regarding short-term risk, NVO is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for NVO.Check SNY's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, GSK has a market cap of 93.2B. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while GSK trades at $46.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas GSK's P/E ratio is 10.05. In terms of profitability, NVO's ROE is +0.59%, compared to GSK's ROE of +0.24%. Regarding short-term risk, NVO is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for NVO.Check GSK's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, BIIB has a market cap of 32.3B. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while BIIB trades at $225.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas BIIB's P/E ratio is 13.79. In terms of profitability, NVO's ROE is +0.59%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, NVO is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for NVO.Check BIIB's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas HZNP's P/E ratio is 61.86. In terms of profitability, NVO's ROE is +0.59%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, NVO is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for NVO.Check HZNP's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, GRFS has a market cap of 6.3B. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while GRFS trades at $7.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas GRFS's P/E ratio is 8.51. In terms of profitability, NVO's ROE is +0.59%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, NVO is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for NVO.Check GRFS's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while OGN trades at $13.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas OGN's P/E ratio is 4.11. In terms of profitability, NVO's ROE is +0.59%, compared to OGN's ROE of +0.23%. Regarding short-term risk, NVO is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for NVO.Check OGN's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, AMRN has a market cap of 248M. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while AMRN trades at $12.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas AMRN's P/E ratio is -119.90. In terms of profitability, NVO's ROE is +0.59%, compared to AMRN's ROE of -0.06%. Regarding short-term risk, NVO is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for NVO.Check AMRN's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, MIRA has a market cap of 29.5M. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while MIRA trades at $0.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas MIRA's P/E ratio is -0.48. In terms of profitability, NVO's ROE is +0.59%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, NVO is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for NVO.Check MIRA's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, SCLX has a market cap of 25.1M. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while SCLX trades at $2.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas SCLX's P/E ratio is -0.08. In terms of profitability, NVO's ROE is +0.59%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, NVO is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for NVO.Check SCLX's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, SCLXW has a market cap of 21M. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while SCLXW trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas SCLXW's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.59%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, NVO is more volatile compared to SCLXW. This indicates higher risk in terms of short-term price fluctuations for NVO.Check SCLXW's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while BDSIW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, NVO's ROE is +0.59%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, NVO is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for NVO.Check BDSIW's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 169.4B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, NVO is priced at $38.64 on the NYSE, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 9.49, whereas CRXT's P/E ratio is -0.02. In terms of profitability, NVO's ROE is +0.59%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, NVO is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for NVO.Check CRXT's competition here